tag:blogger.com,1999:blog-30052762248617072742024-03-13T14:53:43.390-07:00The Keller Laboratory at cc-TDIUnraveling rhabdomyosarcoma, osteosarcoma, dipg and medulloblastoma using engineering, biomedical, and translational research tools.Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.comBlogger379125tag:blogger.com,1999:blog-3005276224861707274.post-81256516264386632832021-12-25T14:07:00.003-08:002021-12-25T14:07:44.419-08:00Our Blog continues at cc-TDI.org<p> Our lab blog continues at https://www.cc-tdi.org/. With gratitude, Charles (charles@cc-tdi.org)</p>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-85410358802723618772016-07-31T21:24:00.002-07:002016-07-31T21:24:13.676-07:00Congratulations, Naren!<span style="font-family: Arial, Helvetica, sans-serif;">Congratulations to Naren for his recent publication of his work performed in his previous fellowship with Dr. Reshma Taneja. This publication entitled, "P/CAF mediates PAX3-FOXO1 dependent oncogenesis
in alveolar rhabdomyosarcoma" can be read <a href="http://www.ncbi.nlm.nih.gov/pubmed/27453350">here</a>. </span>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-8148968295787990642016-02-23T10:13:00.000-08:002016-02-25T10:13:54.178-08:00Rare Disease Day<span style="font-family: Arial, Helvetica, sans-serif;">For a description of this day and the patients affected, see this <a href="http://www.mesothelioma.com/blog/authors/staff/rare-disease-day-2016-how-to-get-involved.htm">blog</a>. </span>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-38043695408976072562015-10-08T16:22:00.001-07:002015-10-08T16:22:16.120-07:00Highlighting Matthew!<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjuT8qXI3V06hviCDdeqVDArwvh1H75XAPXoUS5_9upVrz1_oBYZu423yh4DgxMEfmWPLYhNe4sElASD6MENRYACPIYS5qNhnar5MccoignDnhPurNwwTCVX76vRsJXmbIkeUEYbDnezi4/s1600/MatthewRandolph.JPG" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="146" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjuT8qXI3V06hviCDdeqVDArwvh1H75XAPXoUS5_9upVrz1_oBYZu423yh4DgxMEfmWPLYhNe4sElASD6MENRYACPIYS5qNhnar5MccoignDnhPurNwwTCVX76vRsJXmbIkeUEYbDnezi4/s200/MatthewRandolph.JPG" width="200" /></a></div>
<span style="font-family: Arial, Helvetica, sans-serif;">our Congratulations to Matthew R. whose review on tissue-specific muscle stem cells has just been published. You can see the article <a href="http://dx.doi.org/10.3389/fnagi.2015.00190">here</a>. Matthew wrote this review as part of his work with his PhD mentor, Dr. Grace Pavlath. Matthew's scientific publication from this training is <a href="http://onlinelibrary.wiley.com/doi/10.1113/jphysiol.2014.280420/abstract;jsessionid=C7E7D9476794B2DF5DA8538822A8781F.f02t01">here</a>. </span>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-20723443288459943442015-09-11T10:35:00.000-07:002015-09-11T10:35:28.578-07:00Update: The Alexa Project<div class="separator" style="clear: both; text-align: center;">
<iframe allowfullscreen='allowfullscreen' webkitallowfullscreen='webkitallowfullscreen' mozallowfullscreen='mozallowfullscreen' width='320' height='266' src='https://www.blogger.com/video.g?token=AD6v5dwxGPGRWa_39Cqh4lu4ku17Cr9Hi9qGLRn_iWahIfT6AEfcByEF1rBQCtBA_ailFrE1uJBwH5FWMdOC6jURJg' class='b-hbp-video b-uploaded' frameborder='0'></iframe></div>
<br />Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-42852615418859783372015-07-05T09:30:00.000-07:002015-07-05T09:30:18.894-07:00CURE Childhood Cancer Foundation Awards Multiyear Grant to cc-TDI<a href="http://static.wixstatic.com/media/64891b_31f767b2f10a46b3850e2a0d9026503d.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img alt="" border="0" data-cke-saved-src="http://static.wixstatic.com/media/64891b_31f767b2f10a46b3850e2a0d9026503d.jpg" height="200" post-cover-photo="" src="http://static.wixstatic.com/media/64891b_31f767b2f10a46b3850e2a0d9026503d.jpg" style="outline: rgb(56, 153, 236) solid 2px;" width="154" wix-comp="{"id":"innercomp_txtMedia1b9","dataQuery":"txtMedia1b9","propertyQuery":"txtMedia1b9","componentType":"wysiwyg.viewer.components.WPhoto","styleId":"","skin":"wysiwyg.viewer.skins.photo.NoSkinPhoto","display":"block","marginLeft":"auto","marginRight":"auto","width":1.0007149754108753,"src":"http://static.wixstatic.com/media/64891b_31f767b2f10a46b3850e2a0d9026503d.jpg","isFullSize":false}" /></a><span style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px;">We are pleased to announce that the Children's Cancer Therapy Development Institute was selected to receive a multiyear research grant awarded by CURE Childhood Cancer foundation of Atlanta, GA. The grant will help fund our CUREfast Cancer Registry for Familial and Sporadic Tumors. We have pioneered an approach to the difficult decision that some families make when choosing to donate tissue that provides resources to the scientific community to bring about new knowledge and potential new drug treatments for changed outcomes. We are excited to work with CURE Childhood Cancer and honored to be selected as one of their grantees. </span><br />
<span style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px;"> </span><span style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px;"></span><br />
<div class="cke_widget_wrapper cke_widget_block cke_image_nocaption cke_widget_focused cke_widget_selected" data-cke-display-name="image" data-cke-filter="off" data-cke-widget-id="0" data-cke-widget-wrapper="1" style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px; font-stretch: normal; margin: 0px; outline: none; position: relative;" tabindex="-1">
</div>
<div>
<br /></div>
Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-486471090305055332015-07-05T09:28:00.005-07:002015-07-05T09:28:35.718-07:00Our thanks to the Shenandoah Sharks!<a href="http://static.wixstatic.com/media/64891b_cd1315abba7841cc8272c6a5b31ea2ab.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img alt="" border="0" data-cke-saved-src="http://static.wixstatic.com/media/64891b_cd1315abba7841cc8272c6a5b31ea2ab.jpg" height="144" post-cover-photo="" src="http://static.wixstatic.com/media/64891b_cd1315abba7841cc8272c6a5b31ea2ab.jpg" style="outline: rgb(56, 153, 236) solid 2px;" width="200" wix-comp="{"id":"innercomp_txtMedia71r","dataQuery":"txtMedia71r","propertyQuery":"txtMedia71r","componentType":"wysiwyg.viewer.components.WPhoto","styleId":"","skin":"wysiwyg.viewer.skins.photo.NoSkinPhoto","display":"block","marginLeft":"auto","marginRight":"auto","width":1,"src":"http://static.wixstatic.com/media/64891b_cd1315abba7841cc8272c6a5b31ea2ab.jpg","isFullSize":false}" /></a><span style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px;">We are grateful to </span><span style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px; font-weight: bold;"><span style="font-style: italic;">The Shenandoah Sharks</span></span><span style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px;">, a Summer swim team in Shenandoah, Texas. These swimmers and their families recently held a swim-a-thon in memory of Thomas, the brother to a member of the team, Emily. Thomas had an inconquerable spirit during his battle with childhood cancer. Fittingly, the motto for this event was </span><span style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px; font-style: italic;">Fortitudo: strength-courage-perseverance</span><span style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px;">. Our thanks go to all the swimmers and their families who made this fundraiser possible, and for remembering Thomas in this way. </span><br />
<span style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px;"> </span><br />
<span style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px;">[ pictured: Charles holding the Sharks' t-shirt with Thomas' parents, Beni and Cynthia. ]</span>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-36655400743072382042015-07-05T09:27:00.001-07:002015-07-05T09:27:26.754-07:00Welcoming Cora & Adelae<div style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px; font-stretch: normal; margin: 0px; max-width: 99.9000015258789%;">
<a href="http://static.wixstatic.com/media/64891b_d580f47d7d34447dbe221de2150488b3.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img alt="" border="0" data-cke-saved-src="http://static.wixstatic.com/media/64891b_d580f47d7d34447dbe221de2150488b3.jpg" height="112" post-cover-photo="" src="http://static.wixstatic.com/media/64891b_d580f47d7d34447dbe221de2150488b3.jpg" style="outline: rgb(56, 153, 236) solid 2px;" width="200" wix-comp="{"id":"innercomp_txtMedia51q","dataQuery":"txtMedia51q","propertyQuery":"txtMedia51q","componentType":"wysiwyg.viewer.components.WPhoto","styleId":"","skin":"wysiwyg.viewer.skins.photo.NoSkinPhoto","display":"block","marginLeft":"auto","marginRight":"auto","width":1,"src":"http://static.wixstatic.com/media/64891b_d580f47d7d34447dbe221de2150488b3.jpg","isFullSize":false}" /></a>We are excited to welcome our Summer students to the lab this week.</div>
<div style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px; font-stretch: normal; margin: 0px; max-width: 99.9000015258789%;">
</div>
<div style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px; font-stretch: normal; margin: 0px; max-width: 99.9000015258789%;">
Adelae is an incoming freshman at Bates College. Her project is in our 'skunkworks' of trying to redefine how targeted therapies can be delivered -- by surgeons! This project involves a lot of 3D printing and robots... the type of experience ideal for Adelae's interest in systems biology and neuroscience. </div>
<div style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px; font-stretch: normal; margin: 0px; max-width: 99.9000015258789%;">
</div>
<div style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px; font-stretch: normal; margin: 0px; max-width: 99.9000015258789%;">
Cora is a Chemical Engineering student at University of Massachusetts, entering her Junior year this Fall. Her work will be focused on <span style="text-decoration: underline;"><a dataquery="#txtMedia2dg" href="https://www.blogger.com/null" style="cursor: inherit;">The Alexa Project</a></span>, which will define the resources available for drug discovery in NF1-associated Juvenile Pilocytic Astrocytoma (a form of brain tumor). </div>
<div>
</div>
<div>
<span data-cke-copybin-start="1" style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px;"></span><span style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px;">[ pictured: Adelae (left) and Cora (right) ] </span></div>
Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-23434465067559173762015-07-05T09:24:00.003-07:002015-07-05T09:24:39.098-07:00Matt, our newest muscle stem cell biologist<a href="http://static.wixstatic.com/media/64891b_def8b5fb0a024c69bb43bfd672ae8362.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img alt="" border="0" data-cke-saved-src="http://static.wixstatic.com/media/64891b_def8b5fb0a024c69bb43bfd672ae8362.jpg" height="146" post-cover-photo="" src="http://static.wixstatic.com/media/64891b_def8b5fb0a024c69bb43bfd672ae8362.jpg" style="outline: rgb(56, 153, 236) solid 2px;" width="200" wix-comp="{"id":"innercomp_txtMedia6so","dataQuery":"txtMedia6so","propertyQuery":"txtMedia6so","componentType":"wysiwyg.viewer.components.WPhoto","styleId":"","skin":"wysiwyg.viewer.skins.photo.NoSkinPhoto","display":"block","marginLeft":"auto","marginRight":"auto","width":0.7000000000000001,"src":"http://static.wixstatic.com/media/64891b_def8b5fb0a024c69bb43bfd672ae8362.jpg","isFullSize":false}" /></a><span style="font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px;">We are excited to welcome Matt to our cc-TDI scientific team. Dr. Matthew Randolph earned his Doctorate of Veterinary Medicine in 2000 from the University of Georgia College of Veterinary Medicine. He practiced mixed animal medicine as an associate veterinarian in northeast Georgia for five years. Matthew then pursued a career in cancer research and recently trained as a stem cell biologist at Emory University, in the laboratory of Dr. Grace Pavlath, while earning his PhD in Biochemistry, Cell, and Developmental Biology. He has joined cc-TDI as a post-doctoral researcher and will investigate novel therapies for childhood cancers, including the cancer of muscle, rhabdomyosarcoma. Matthew and his wife, Casey, enjoy hiking, working with children, and watching science-fiction shows.</span>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-86189418361054913152015-05-05T14:00:00.000-07:002015-05-14T01:48:24.788-07:00Scientists from 13 institutions worldwide collaborate to discover promising therapy for DIPG<span class="Apple-style-span" style="color: white; font-family: Arial, Helvetica, sans-serif;"></span><br />
<div class="MsoNormal">
<span class="Apple-style-span" style="color: white; font-family: Arial, Helvetica, sans-serif;"><span style="font-size: 10.5pt;">Unprecedented international coalition
led to breakthrough for patients with deadliest form of childhood brain cancer,
as released today in Nature Medicine.<o:p></o:p></span></span></div>
<div class="MsoNormal">
<span class="Apple-style-span" style="color: white; font-family: Arial, Helvetica, sans-serif;"><span style="font-size: 10.5pt;"><br /></span></span></div>
<div class="separator" style="clear: both; text-align: center;">
<span class="Apple-style-span" style="color: white; font-family: Arial, Helvetica, sans-serif;"><a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgGpcBKZ-oID7KDSsy9MkYNFtdqAXsG7m64MUa05tJa_ldFTLquQs-JRGatjcQU1qWXixYmxLikbgX8qfvt5rwROzYqgmpbFDx3bzOYiaV6sKk2eDBCGk6b85CNMHbTdE2t0WuYoRV8Svs/s1600/dipg.png" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="139" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgGpcBKZ-oID7KDSsy9MkYNFtdqAXsG7m64MUa05tJa_ldFTLquQs-JRGatjcQU1qWXixYmxLikbgX8qfvt5rwROzYqgmpbFDx3bzOYiaV6sKk2eDBCGk6b85CNMHbTdE2t0WuYoRV8Svs/s320/dipg.png" width="320" /></a></span></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span class="Apple-style-span" style="color: white; font-family: Arial, Helvetica, sans-serif;"><span style="background-attachment: initial; background-clip: initial; background-color: black; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-color: windowtext; border-bottom-style: none; border-bottom-width: 1pt; border-left-color: windowtext; border-left-style: none; border-left-width: 1pt; border-right-color: windowtext; border-right-style: none; border-right-width: 1pt; border-top-color: windowtext; border-top-style: none; border-top-width: 1pt; font-size: 10.5pt; padding-bottom: 0in; padding-left: 0in; padding-right: 0in; padding-top: 0in;"></span><span style="font-size: 10.5pt;"><o:p></o:p></span></span></div>
<span class="Apple-style-span" style="color: white; font-family: Arial, Helvetica, sans-serif;">
</span><br />
<div class="MsoNormal">
<!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:rect
id="Rectangle_x0020_8" o:spid="_x0000_s1029" alt="data:image/gif;base64,R0lGODlhAQABAPABAP///wAAACH5BAEKAAAALAAAAAABAAEAAAICRAEAOw=="
style='width:11.35pt;height:11.35pt;visibility:visible;mso-wrap-style:square;
mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
mso-position-horizontal-relative:char;mso-position-vertical:absolute;
mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
<o:lock v:ext="edit" aspectratio="t"/>
<w:wrap type="none"/>
<w:anchorlock/>
</v:rect><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
id="_x0000_i1031" type="#_x0000_t75" style='width:11.35pt;height:11.35pt'>
<v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--><span class="Apple-style-span" style="color: white; font-family: Arial, Helvetica, sans-serif;"><span style="font-size: 10.5pt;"><o:p></o:p></span></span></div>
<span class="Apple-style-span" style="color: white; font-family: Arial, Helvetica, sans-serif;">
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">[press release] FORT COLLINS, CO,
May 4, 2015 – Researchers from an international coalition of 13 institutions
have discovered a promising combination drug therapy for the deadly childhood
cancer Diffuse Intrinsic Pontine Glioma (DIPG). In a study <u>published
today in <i>Nature Medicine</i></u> co-authored by Michelle Monje,
MD, PhD (Stanford University) and Charles Keller, MD (Children’s Cancer Therapy
Development Institute), the consortium reports that testing of panobinostat,
with or without the histone demethylase inhibitor GSKJ4, may be a promising
therapeutic strategy for this deadly pediatric brain tumor. <o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">DIPG is a rare tumor of the brainstem
that occurs almost exclusively in children under 10 years old. It represents
one of the most devastating diagnoses among pediatric cancers, with an average
survival rate of just nine months. As co-Chairs of the Children’s Oncology
Group brain tumor new drugs committee, Dr. Keller and Dr. Maryam Fouladi built
and coordinated the group of basic and translational scientists who formed the
unprecedented coalition. The project was sponsored by the Lyla Nsouli
Foundation, The CureStartsNow, Curesearch and Accelerate Brain Cancer Cures and
supported by multiple gifts of tumor tissue from children who did not survive.<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">“The story of how the consortium
started is a fun one,” explained Keller. “In a packed St Louis hotel meeting
room a few years ago, our committee put forth ideas for the next DIPG clinical
trial. It became clear that the nation’s best oncologists had lots of ideas,
but we all had no data…so we decided to have a “bake-off”. Maryam rallied the
pediatric neuro-oncologists, and I coordinated and recruited the research
teams. Eighty-three drugs later, we have an answer.”<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">The work began with a chemical screen
in patient-derived DIPG cultures along with RNAseq analyses and integrated
computational modeling to identify potentially effective therapeutic
strategies. The multi-histone deacetylase inhibitor panobinostat demonstrated
efficacy in vitro and in DIPG orthotopic xenograft (mouse) models. Further
testing of panobinostat with histone demethylase inhibitor GSKJ4 revealed
synergy in combination. A clinical trial is currently being designed for
single-drug therapy with panobinostat, which will likely begin enrolling
patients later this year.<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">“This panobinostat clinical trial is
really the first step,” Keller said. “We can be fairly certain that as the
‘world’s most difficult cancer to treat,’ DIPG will take more than one drug to
cure. As promising as the panobinostat-GSKJ4 combination is, we may need to go
further—even exploring non-traditional compounds not yet used as medicines.”<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">The full consortium includes:<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Charles Keller, MD - Children's Cancer
Therapy Development Institute (co-corresponding author)<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Michelle Monje, MD, PhD - Stanford
University (co-corresponding author)<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal" style="margin-bottom: 12.0pt;">
<span style="font-size: 10.5pt;">Marta Alonso, MD - University of Navarra, Madrid, Spain<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Oren Becher, MD - Duke University
Medical Center<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Mariko DeWire, MD - Nationwide
Children's Hospital<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Maryam Fouladi, MD - Cincinnati
Children's Hospital Medical Center<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Jacques Grill, MD, PhD - Institut
Gustave-Roussy, Villejuif, France<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Cynthia Hawkins, MD, PhD - University
of Toronto<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Xiao-Nan Li, MD, PhD - Baylor College
of Medicine<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Dannis G. van Vuurden, MD, MSc, &
Esther Hulleman - VU Cancer Center Amsterdam<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Eric H. Raabe, MD - Johns Hopkins
University<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Dennis Steindler, PhD - University of
Florida<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Katherine Warren, MD, Paul Meltzer, MD,
PhD, and Martha Quezado, MD - National Institutes of Health<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">“The manuscript by Grasso, Tang,
Truffaux et al is an outstanding example of cooperation among dedicated
laboratory based scientists and clinicians who have pooled resources and freely
shared data to impact the treatment of a rare but fatal brain tumor in
children. A special recognition should be given to community-based
organizations that provided philanthropic support to enable the study. This
model of translational research should be encouraged and fostered to improve
outcome for rare human disease,” said Amar Gajjar, MD, Chair of the Central
Nervous System Tumor Committee, Children's Oncology Group and neuro-oncologist
at St. Jude Children’s Research Hospital.<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">“In a disease where no therapeutic
progress has been made in several decades, we see the culmination of
the efforts of an international group of basic and translational
investigators who have collaborated together to better
understand potential therapeutic targets and conduct preclinical testing
of promising agents targeting relevant pathways in this deadly disease.
The fact that Drs. Monje & Keller and colleagues demonstrated that the
combination of panobinostat and the GSKJ4 demonstrate synergy is very
promising. The Children’s Oncology Group was the catalyst for fostering these
efforts over the past three years, with funding coming from philanthropic
agencies who also banded together to support these efforts. The next step
is to develop clinical trials to assess the efficacy of these agents alone
and in combination in patients with DIPG. Based on data presented in this
paper, the Pediatric Brain Tumor Consortium is moving forward with a new study
to test panobinostat in children with newly diagnosed and recurrent
DIPGs. I hope that the results generated from these
critical preclinical collaborations will lead to the development of novel
combination trial strategies to effectively treat children with this
deadly tumor,” said Maryam Fouladi, MD, Chair of the Pediatric Brain Tumor
Consortium Steering Committee and Medical Director of the Neuro-Oncology
Program at Cincinnati Children’s Hospital Medical Center.<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjWnpB1fFgjRGzxhddJ9ztthcJzzBzj-XWeLafioX18-y7dvy8Nt3asUX_NM9hIoIGMtzgFTTKtVzV0cCaTRVcn2vxPLIPV0dqsQxu6AVY9A5Cb69mShJLnIxe3CLN9fjQ0HZt2fjKhZQs/s1600/Alexis-Agin-and-parents.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="179" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjWnpB1fFgjRGzxhddJ9ztthcJzzBzj-XWeLafioX18-y7dvy8Nt3asUX_NM9hIoIGMtzgFTTKtVzV0cCaTRVcn2vxPLIPV0dqsQxu6AVY9A5Cb69mShJLnIxe3CLN9fjQ0HZt2fjKhZQs/s320/Alexis-Agin-and-parents.jpg" width="320" /></a></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-color: black; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-color: windowtext; border-bottom-style: none; border-bottom-width: 1pt; border-left-color: windowtext; border-left-style: none; border-left-width: 1pt; border-right-color: windowtext; border-right-style: none; border-right-width: 1pt; border-top-color: windowtext; border-top-style: none; border-top-width: 1pt; font-size: 10.5pt; padding-bottom: 0in; padding-left: 0in; padding-right: 0in; padding-top: 0in;"></span><span style="font-size: 10.5pt;"><o:p></o:p></span></div>
<div class="MsoNormal">
<!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:rect
id="Rectangle_x0020_6" o:spid="_x0000_s1028" alt="data:image/gif;base64,R0lGODlhAQABAPABAP///wAAACH5BAEKAAAALAAAAAABAAEAAAICRAEAOw=="
style='width:11.35pt;height:11.35pt;visibility:visible;mso-wrap-style:square;
mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
mso-position-horizontal-relative:char;mso-position-vertical:absolute;
mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
<o:lock v:ext="edit" aspectratio="t"/>
<w:wrap type="none"/>
<w:anchorlock/>
</v:rect><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
id="_x0000_i1029" type="#_x0000_t75" style='width:11.35pt;height:11.35pt'>
<v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--><span style="font-size: 10.5pt;"><o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">"For as long as DIPG has been
specifically classified, parents of children diagnosed with this cancer have
longed for effective treatments. This represents an exciting and promising
new chapter that finally provides hope. Since the time of my daughter Alexis'
diagnosis in April 2008, and her passing in January 2011, little has
changed…until now. I am beyond hopeful that this now represents that
change,” said Jonathan Agin, childhood cancer advocate and cc-TDI General
Counsel. Agin lost his daughter Alexis to DIPG when she was two weeks away from
her fifth birthday.<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjYDrb5yAFtZNYOR1BscFRx5xypv6g9JFKxCVcK-u4bRZR-9fqkRTP9hHvfHforoznoLOD7k8KamkzTxT6XxuMHmQUlF9Cw4HaQI5wrF7AlVhvFuACITv3A9sd6t7YzotpZ6Z10rpgmZ3U/s1600/lyla.JPG" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="320" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjYDrb5yAFtZNYOR1BscFRx5xypv6g9JFKxCVcK-u4bRZR-9fqkRTP9hHvfHforoznoLOD7k8KamkzTxT6XxuMHmQUlF9Cw4HaQI5wrF7AlVhvFuACITv3A9sd6t7YzotpZ6Z10rpgmZ3U/s320/lyla.JPG" width="213" /></a></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-color: black; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-color: windowtext; border-bottom-style: none; border-bottom-width: 1pt; border-left-color: windowtext; border-left-style: none; border-left-width: 1pt; border-right-color: windowtext; border-right-style: none; border-right-width: 1pt; border-top-color: windowtext; border-top-style: none; border-top-width: 1pt; font-size: 10.5pt; padding-bottom: 0in; padding-left: 0in; padding-right: 0in; padding-top: 0in;"></span><span style="font-size: 10.5pt;"><o:p></o:p></span></div>
<div class="MsoNormal">
<!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:rect
id="Rectangle_x0020_4" o:spid="_x0000_s1027" alt="data:image/gif;base64,R0lGODlhAQABAPABAP///wAAACH5BAEKAAAALAAAAAABAAEAAAICRAEAOw=="
style='width:11.35pt;height:11.35pt;visibility:visible;mso-wrap-style:square;
mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
mso-position-horizontal-relative:char;mso-position-vertical:absolute;
mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
<o:lock v:ext="edit" aspectratio="t"/>
<w:wrap type="none"/>
<w:anchorlock/>
</v:rect><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
id="_x0000_i1027" type="#_x0000_t75" style='width:11.35pt;height:11.35pt'>
<v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--><span style="font-size: 10.5pt;"><o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">"We are very enthusiastic about
the work of Dr. Keller, Dr. Monje and the DIPG consortium and are excited by
the study findings about panobinostat. This drug offers a new path of study
with the potential to create treatment options for DIPG. We look forward to the
next steps of research and are hopeful that this progress brings us closer to
helping children with DIPG to survive.”<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Based in Fort Collins, Colorado, the
Children's Cancer Therapy Development Institute is a unique research group that
is focused on closing what is known as the "pre-clinical gap" in
childhood cancer research. To end the stalemate in curing childhood cancers,
cc-TDI is dedicated to translating knowledge from basic scientific advancements
into proven, viable treatment options that can be tested in clinical trials,”
comments Nadim Nsouli on behalf of the Lyla Nsouli Foundation, the principal
sponsor of the international research effort. Mr. Nsouli, and his wife Simone,
founded the Lyla Nsouli Foundation after the passing of their 4 year old
daughter, Lyla, as a result of DIPG. Her mother adds, “We miss Lyla
terribly. She was truly our pride and joy.” <o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjfyAbvlBf9oGhzH94Nz0Twu7PTLxvSY7gD5DUXh6KqjvXycUzkZRbDni5pkvdVrX3UR8k5qK7KBWbzAYCVYzs5ie6UN5g1tvQrIjXxb9jyenIS7xXGN4VAZ-mC1yp5Rx1-ksureaRaD4Q/s1600/Andrew-Smith_with+Mom.jpg" imageanchor="1" style="margin-left: 1em; margin-right: 1em;"><img border="0" height="212" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjfyAbvlBf9oGhzH94Nz0Twu7PTLxvSY7gD5DUXh6KqjvXycUzkZRbDni5pkvdVrX3UR8k5qK7KBWbzAYCVYzs5ie6UN5g1tvQrIjXxb9jyenIS7xXGN4VAZ-mC1yp5Rx1-ksureaRaD4Q/s320/Andrew-Smith_with+Mom.jpg" width="320" /></a></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<span style="background-attachment: initial; background-clip: initial; background-color: black; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-color: windowtext; border-bottom-style: none; border-bottom-width: 1pt; border-left-color: windowtext; border-left-style: none; border-left-width: 1pt; border-right-color: windowtext; border-right-style: none; border-right-width: 1pt; border-top-color: windowtext; border-top-style: none; border-top-width: 1pt; font-size: 10.5pt; padding-bottom: 0in; padding-left: 0in; padding-right: 0in; padding-top: 0in;"></span><span style="font-size: 10.5pt;"><o:p></o:p></span></div>
<div class="MsoNormal">
<!--[if mso & !supportInlineShapes & supportFields]><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span><![endif]--><!--[if gte vml 1]><v:rect
id="Rectangle_x0020_2" o:spid="_x0000_s1026" alt="data:image/gif;base64,R0lGODlhAQABAPABAP///wAAACH5BAEKAAAALAAAAAABAAEAAAICRAEAOw=="
style='width:11.35pt;height:11.35pt;visibility:visible;mso-wrap-style:square;
mso-left-percent:-10001;mso-top-percent:-10001;mso-position-horizontal:absolute;
mso-position-horizontal-relative:char;mso-position-vertical:absolute;
mso-position-vertical-relative:line;mso-left-percent:-10001;mso-top-percent:-10001;
v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
<o:lock v:ext="edit" aspectratio="t"/>
<w:wrap type="none"/>
<w:anchorlock/>
</v:rect><![endif]--><!--[if mso & !supportInlineShapes & supportFields]><v:shape
id="_x0000_i1025" type="#_x0000_t75" style='width:11.35pt;height:11.35pt'>
<v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span><![endif]--><span style="font-size: 10.5pt;"><o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Sandy Smith, an advocate for childhood
cancer and a cancer survivor herself offered this perspective: “I was diagnosed
with breast cancer on Monday, October 22, 2007. My 6-year-old son Andrew was
diagnosed with diffuse intrinsic pontine glioma (DIPG) just a few days later.
We both ended up with ports, we both did chemotherapy and radiation, and we
both lost our hair; but that’s where the similarities end. My treatment was
standard and my prognosis favorable. There was no hope of a cure for Andrew;
radiation was palliative. While we pushed through my treatment, my husband and
I did our best to savor every moment with our son because we knew those moments
were very limited. This publication—the result of selfless collaboration by
dedicated scientists from around the world—is a step toward progress for
children with DIPG. This is meaningful science making a difference in the lives
of children and families like mine.”<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">“This is a journey and a partnership
with families. One of the most interesting features of the project is
that we kept a <u>weekly blog</u> of research activities - which
allowed families to follow progress with us (and give feedback). We still need
more tissue, better cell lines, and more mouse models. Our 15 institutions
are unified by the community support that brought us together and keeps us
focused. We’ll continue pursuing better and better treatments until the day<br />
that DIPG is uniformly survivable,” Keller added.<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">For more on cc-TDI’s efforts to move
scientific discoveries to clinical trials for children with cancers like DIPG,
visit www.cc-TDI.org.<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">[ full funding acknowledgements: This
research was supported by the Lyla Nsouli Foundation, the Children’s Oncology
Group (COG) Central Nervous System Committee, the DIPG Collaborative (The Cure
Starts Now Foundation, Reflections of Grace Foundation, Smiles for Sophie
Foundation, Cancer-Free Kids Foundation, Carly’s Crusade Foundation, Jeffrey
Thomas Hayden Foundation, Soar with Grace Foundation), the Accelerate Brain
Cancer Cures Foundation (ABC2), CureSearch for Childhood Cancer, the Team
Julian Foundation and the COG Chair’s Grant (5UOCA098543). Additional funding
support was provided by US National Institutes of Health grant K08NS070926 (to
author M.M.), Alex’s Lemonade Stand Foundation (to M.M. and Y.T.), the
McKenna Claire Foundation, the Connor Johnson Memorial Fund, the Dylan Jewett
Memorial Fund, the Elizabeth Stein Memorial Fund, the Dylan Frick Memorial
Fund, the Abigail Jensen Memorial Fund, the Zoey Ganesh Memorial Fund, the
Wayland Villars DIPG Foundation, the Jennifer Kranz Memorial Fund, Unravel Pediatric
Cancer, the Virginia & D.K. Ludwig Fund for Cancer Research, the Price
Family Charitable Fund, the Matthew Larson Foundation, the Godfrey Family Fund
in Memory of Fiona Penelope, the Child Health Research Institute at Stanford,
the Anne T. and Robert M. Bass Endowed Faculty Scholarship in Pediatric
Cancer and Blood Diseases (all to M.M.), Etoile de Martin (to J.G. and
N.T.), Fondation Lemos and Le Défi de Fortunée (to J.G.), the Scott
Carter Foundation (to N.E.B.), the Semmy Foundation (to D.G.v.V. and
E.H.), the US Department of Defense (to X.-N.L.), National Science
Foundation grant CCF0953366 (to R.P.), Marie Curie grant IRG270459 (to M.M.A.);
the Spanish Ministry of Health grant PI13/0125 (to M.M.A.), and the St.
Baldrick’s Foundation and Iron Matt Foundation (both to E.R. and
M.H.-C.). ]<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">###<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">About Children’s Cancer Therapy
Development Institute<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">The Children's Cancer Therapy
Development Institute was created with one aim: to make childhood cancer
universally survivable, regardless of diagnosis. Our mission is to
translate scientific discovery into clinical trials by understanding and
proving new disease-specific treatment options for children with cancer. Our
team, led by Scientific Director Charles Keller, MD, is discovering and proving
new disease-specific treatments in our Innosphere lab at the base of the Rocky
Mountains.<o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Contact: Charles Keller, MD<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">(970) 239-4296 |
charles@cc-TDI.org<o:p></o:p></span></div>
<div class="MsoNormal">
<span style="font-size: 10.5pt;">Jonathan Agin | (703)
371-0218 <o:p></o:p></span></div>
<div class="MsoNormal">
<br /></div>
<div align="center" class="MsoNormal" style="text-align: center;">
<br />
<br />
<div style="text-align: left;">
coverage in Lancet Oncology: http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2815%2970230-5/abstract</div>
<div style="text-align: left;">
<br /></div>
</div>
</span>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-45666556960293177312015-04-24T05:22:00.001-07:002015-04-24T05:22:43.259-07:00rhabdomyosarcoma conference at NCI<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh99RnHLQnFihohNasSMZDdcdCly7HD1Vumlvf1Wvr-WEWQNiQIveWWfNUc7-UErpMgpuE1sSvVixZut_R-R2bMsmCPlg5ZR97J0QYG4NolDHXI3VRpkp95k6roeuhaLCxDJQMHDbb-nik/s1600/nci-rms-conf.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEh99RnHLQnFihohNasSMZDdcdCly7HD1Vumlvf1Wvr-WEWQNiQIveWWfNUc7-UErpMgpuE1sSvVixZut_R-R2bMsmCPlg5ZR97J0QYG4NolDHXI3VRpkp95k6roeuhaLCxDJQMHDbb-nik/s1600/nci-rms-conf.jpg" height="177" width="320" /></a><span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">Our thanks to Javed Khan for hosting the <a href="http://ncifrederick.cancer.gov/events/Rhabdomyosarcoma/">NCI Targeting Rhabdomyosarcoma Workshop</a> this week in Gaithersburg. Highlights included the interaction of muscle biologists and those who study rhabdomyosarcoma. </span><br />
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;"><br /></span>
<br />Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-48197946702265482932015-04-22T10:49:00.002-07:002015-04-22T10:51:31.958-07:00AACR 2015<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;"><br /></span>
<br />
<div class="MsoNormal" style="background-attachment: initial; background-clip: initial; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEivOVfIF2nDOq4ase40qM6nF5H91YIEqykck8aGHNXFVHNO_6Ma5VJ8SZUEENkxkI-dsBWKzEUTMtu6uEsYBz7d5DEeS1eKyEQKqi9E29xNcVHaqU9GKiQk9ZjRGgQGXk3n3sRI9rSc8_w/s1600/philly-aacr.JPG" imageanchor="1" style="background-color: white; clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><span class="Apple-style-span" style="color: black; font-family: Arial, Helvetica, sans-serif;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEivOVfIF2nDOq4ase40qM6nF5H91YIEqykck8aGHNXFVHNO_6Ma5VJ8SZUEENkxkI-dsBWKzEUTMtu6uEsYBz7d5DEeS1eKyEQKqi9E29xNcVHaqU9GKiQk9ZjRGgQGXk3n3sRI9rSc8_w/s1600/philly-aacr.JPG" height="200" width="149" /></span></a><span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">The 2015 Annual AACR in Philadelphia meeting concludes today. It was a particular honor for Dr. Keller to present with his career mentor, 2007 Nobel laureate Mario Capecchi at the session, <i>Modeling Human Sarcomas: Recent Advances in Organ Site Research</i>. On Sunday, Dr. Capecchi received the lifetime career award from the AACR. </span></div>
Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-91547076766484206252015-03-21T18:24:00.001-07:002015-03-21T18:24:22.950-07:00Mayo Clinic seminar<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi9R2eaXTcrONUP1_1JSjHWXu7ISYRzcWwhBwYoJlc_H5OTqvQdqDqyWyw-xEiaBfQF-9keE_RpQi_rsaixsfhZiKPg6cw_Bsvx7E10TuGu-5EqMIpBdObee8uRwODkWKxHw4-p2b5V-1g/s1600/jax-airport.JPG" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEi9R2eaXTcrONUP1_1JSjHWXu7ISYRzcWwhBwYoJlc_H5OTqvQdqDqyWyw-xEiaBfQF-9keE_RpQi_rsaixsfhZiKPg6cw_Bsvx7E10TuGu-5EqMIpBdObee8uRwODkWKxHw4-p2b5V-1g/s1600/jax-airport.JPG" height="146" width="200" /></a><span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">My thanks to hosts Drs. Aubrey Thompson and Al Copland for the opportunity to present our work at cc-TDI in their seminar series. It was a very productive visit - with new collaborations formed, and special traction on the Xp11 RCC effort. </span>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-56026372001454184072015-03-11T23:32:00.001-07:002015-03-19T00:10:20.052-07:00Congratulations, Mat!<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEimEvrpCLU1Pv-YHokzJ5AgetlFnVkdTCMFR9FwxE1O4wBBcWwgOYIOuFTa6cNO3OSQpfsCfF7MO9FMTtPFeDWDtTV4fvCBolSgdrtEBNPgRhrEEVaJDeudYO2wL69WUlolwspHuZ4H2Xk/s1600/Mat.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><span style="font-family: Arial, Helvetica, sans-serif;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEimEvrpCLU1Pv-YHokzJ5AgetlFnVkdTCMFR9FwxE1O4wBBcWwgOYIOuFTa6cNO3OSQpfsCfF7MO9FMTtPFeDWDtTV4fvCBolSgdrtEBNPgRhrEEVaJDeudYO2wL69WUlolwspHuZ4H2Xk/s1600/Mat.jpg" height="200" width="143" /></span></a><span style="font-family: Arial, Helvetica, sans-serif;">Mat's manuscript on head & neck pediatric rhabdomyosarcoma was accepted today to <i><a href="http://www.frontiersin.org/Pediatric_Oncology">Frontiers in Oncology, Pediatric Oncology</a></i>. Co-authors include lab alumni Jinu and GH. This work was supported in part by the <a href="http://www.ethanjostadfoundation.org/">Ethan Jostad Foundation</a>. stay tuned for the e-release of the paper! </span><br />
<span style="font-family: Arial, Helvetica, sans-serif;"> </span><br />
<span style="font-family: Arial, Helvetica, sans-serif;">[ 03/19/2015 update: Mat's article is now published online <a href="http://journal.frontiersin.org/article/10.3389/fonc.2015.00074/abstract">here</a> ]</span>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-86898699937794205072015-03-02T10:59:00.004-08:002015-03-02T11:00:44.023-08:00Purdue Cancer Center seminar<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiqPZ48_e9ppnsIx8p2hurAWHVgYqscXOAUzEcdBFa08Etrw-HXfYcYR06O3TeVgg3Hy0Zr8_4B56mPQgNlJlnH9XQU-JHv-a_GlQ1ba7tb9KM1Sa2BaqpndHvOz9fLVoNco3wROc1T6uE/s1600/Keller+2-26.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiqPZ48_e9ppnsIx8p2hurAWHVgYqscXOAUzEcdBFa08Etrw-HXfYcYR06O3TeVgg3Hy0Zr8_4B56mPQgNlJlnH9XQU-JHv-a_GlQ1ba7tb9KM1Sa2BaqpndHvOz9fLVoNco3wROc1T6uE/s1600/Keller+2-26.jpg" height="76" width="320" /></a><span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">My thanks to hosts Drs. Shihuan Kuang and Timothy Ratliff for the opportunity to present our work at the Purdue University Center for Cancer Research seminar series on February 26. Purdue has exciting programs in muscle & non-muscle stem cell biology & physiology and tissue engineering, and cancer biology. It was a pleasure to meet with these accomplished scientists and build new collaborations. </span><br />
<br />
<br />Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-43933648451555887142015-03-01T12:40:00.001-08:002015-03-01T12:41:35.698-08:00NCI Targeting Rhabdomyosarcoma Workshop<a href="http://ncifrederick.cancer.gov/events/Rhabdomyosarcoma/images/top-right.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"></a><span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif; font-size: x-small;"><i>reposted from <a href="http://ncifrederick.cancer.gov/events/Rhabdomyosarcoma/">http://ncifrederick.cancer.gov/events/Rhabdomyosarcoma/</a> </i></span><br />
<div class="separator" style="clear: both; text-align: center;">
<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiZynJ1TnuXPEn82mw0OYXW6Rq1PlcFbsjD81W2D-llbY2dLWOE8KfiRCQJpaVJtzSN0qKPVVdDyPsd33wcdZUR_XzXB-kGpkwwpjzf_6TpMVN-B8q1Ok3_XVH-_ggIXQanpYhSja_5BPc/s1600/graphic-nci-rms.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiZynJ1TnuXPEn82mw0OYXW6Rq1PlcFbsjD81W2D-llbY2dLWOE8KfiRCQJpaVJtzSN0qKPVVdDyPsd33wcdZUR_XzXB-kGpkwwpjzf_6TpMVN-B8q1Ok3_XVH-_ggIXQanpYhSja_5BPc/s1600/graphic-nci-rms.jpg" /></a></div>
<br />
<br />
<h1 style="-webkit-text-stroke-width: 0px; color: #00629d; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 16px; font-style: normal; font-variant: normal; font-weight: bold; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;">
<span class="Apple-style-span" style="color: black; font-size: 12px; font-weight: normal;"></span></h1>
<div style="-webkit-text-stroke-width: 0px; color: black; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;">
<strong><span class="Apple-style-span" style="color: white;">NCI Shady Grove<br />8717 Grovemont Circle<br />Gaithersburg, MD 20877</span></strong></div>
<div style="-webkit-text-stroke-width: 0px; color: black; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;">
<strong><span class="Apple-style-span" style="color: white;">Host Institute</span></strong><br />
<span class="Apple-style-span" style="color: white;">Genetics Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health</span></div>
<div style="-webkit-text-stroke-width: 0px; color: black; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;">
<strong><span class="Apple-style-span" style="color: white;"><br /></span></strong></div>
<div style="-webkit-text-stroke-width: 0px; color: black; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;">
<strong><span class="Apple-style-span" style="color: white;">Background</span></strong><br />
<span class="Apple-style-span" style="color: white;">Rhabdomyosarcoma (RMS) is the third most common extracranial solid tumor of childhood. Approximately 350 new cases are diagnosed in the United States each year accounting for 3 percent of childhood cancers. RMS is derived from primitive myoblasts and morphologically resembles early stages of prenatal skeletal muscle differentiation. However, a large percentage of RMS tumors occur in locations normally lacking skeletal muscle, with the head and neck, genitourinary tract and retroperitoneum being frequent sites of tumor localization. Development of RMS has been associated with genetic tumor predisposition syndromes including Li-Fraumeni syndrome, neurofibromatosis and Costello syndrome. Childhood RMS is subdivided into two major subtypes, embryonal and alveolar, which have distinct histological features and genetic alterations. Adult RMS is largely a third histological subtype, namely pleomorphic RMS. The alveolar RMS subtype carries a poorer prognosis and is strongly myogenin positive by immunohistochemistry. The embryonal RMS subtype carries a better prognosis and is strongly MYOD1 positive by immunohistochemistry. Treatment for RMS is typically multidisciplinary including surgical resection, chemotherapy and radiation therapy. Relapse-free survival rates with this aggressive treatment regimen approach 70-80% for patients with localized disease. However, the 5-year survival rate for patients with metastatic disease at diagnosis continues to be less than 30%. Improvement in these survival rates is dependent upon identification of RMS-specific molecularly targeted agents.</span></div>
<div style="-webkit-text-stroke-width: 0px; color: black; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;">
<span class="Apple-style-span" style="color: white;">Recent next-generation sequencing efforts have highlighted several driver mutations in RMS. The drivers for ARMS include the PAX3-FOXO1 and PAX7-FOXO1chimeric transcription factors. In contrast, the drivers for ERMS include mutations in the FGFR4/RAS signaling pathway, loss of heterozygosity at 11p15 (leading to IGF2 overexpression) and chromosome 8 gains. The prognostic significance of these mutations is currently unknown. Of these drivers, only IGF1R has been targeted in clinical trials in RMS, through the use of therapeutic monoclonal antibodies. These agents, including cixutumumab, show limited single agent activity and efficacy is limited by tumor resistance to the targeted agent. Small molecule inhibitors of the RAS-MAP kinase pathway, receptor tyrosine kinases, and reactive oxygen species have been validated and tested in other cancer types. In addition, targeted agents directed against other chimeric transcription factors, such as EWS-FLI1, have been identified. Validation of these targeted agents in RMS is complicated by the lack of a universal pre-clinical animal model of ERMS or ARMS.</span></div>
<div style="-webkit-text-stroke-width: 0px; color: black; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;">
<span class="Apple-style-span" style="color: white;"><br /></span></div>
<div style="-webkit-text-stroke-width: 0px; color: black; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;">
<span class="Apple-style-span" style="color: white;">The purpose of this meeting is to bring together the leaders in rhabdomyosarcoma basic, genomic, translational and clinical research to share ideas, data, resources and plan for collaborative and synergistic approaches to decipher rhabdomyosarcoma biology and develop novel therapies.</span></div>
<div style="-webkit-text-stroke-width: 0px; color: black; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;">
<strong><span class="Apple-style-span" style="color: white;"><br /></span></strong></div>
<div style="-webkit-text-stroke-width: 0px; color: black; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;">
<strong><span class="Apple-style-span" style="color: white;">Planning committee</span></strong><br />
<span class="Apple-style-span" style="color: white;">Javed Khan, Fred Barr, Doug Hawkins, Stephen Skapek, Janet Shipley, David Langenau, Charles Keller, Mari Yohe</span></div>
<div style="-webkit-text-stroke-width: 0px; color: black; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;">
<strong><span class="Apple-style-span" style="color: white;"><br /></span></strong></div>
<div style="-webkit-text-stroke-width: 0px; color: black; font-family: Arial, Helvetica, Verdana, sans-serif; font-size: 12px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; orphans: auto; text-align: left; text-indent: 0px; text-transform: none; white-space: normal; widows: auto; word-spacing: 0px;">
<strong><span class="Apple-style-span" style="color: white;">Funding Sources</span></strong><br />
<span class="Apple-style-span" style="color: white;">Office of Rare Disease (ORDR; <a href="http://rarediseases.info.nih.gov/" style="text-decoration: underline;" target="_blank">http://rarediseases.info.nih.gov/</a>)</span><br />
<span class="Apple-style-span" style="color: white;">Center for Cancer Research (CCR; <a href="https://ccr.cancer.gov/" style="text-decoration: underline;" target="_blank">https://ccr.cancer.gov/</a>)</span></div>
Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-85438460988314202012015-02-02T20:33:00.001-08:002015-02-02T20:33:17.466-08:00Hope in the Huffington Post<br />
<div style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; max-width: 99.9000015258789%; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: start; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; word-spacing: 0px;">
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">The Children's Cancer Therapy Development Institute was <span style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: underline; vertical-align: baseline;"><a dataquery="#blog_25BD3864" href="" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-color: blue; border-bottom-style: dotted; border-left-width: 0px; border-right-width: 0px; border-top-width: 0px; cursor: inherit; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: none; vertical-align: baseline;">profiled in the <span style="background: transparent; border: 0px; font-style: italic; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;">Huffington Post</span></a></span> today! </span></div>
<div style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; max-width: 99.9000015258789%; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: start; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; word-spacing: 0px;">
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;"><br /></span></div>
<img data-cke-saved-src="http://static.wixstatic.com/media/64891b_0991976ce8a94d18bbf7448779988964.png" src="http://static.wixstatic.com/media/64891b_0991976ce8a94d18bbf7448779988964.png" style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; clear: both; cursor: default; display: block; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 19.6000003814697px; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 10px; max-width: 100%; outline-color: rgb(0, 153, 255); outline-style: solid; outline-width: 2px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: start; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; width: 585.555541992188px; word-spacing: 0px;" wix-comp="{"id":"innercomp_txtMedia6fz","dataQuery":"txtMedia6fz","propertyQuery":"txtMedia6fz","componentType":"wysiwyg.viewer.components.WPhoto","styleId":"","skin":"wysiwyg.viewer.skins.photo.NoSkinPhoto","display":"block","marginLeft":"auto","marginRight":"auto","dimsRatio":0.4461805555555556,"defaultWidth":576,"width":1}" /><div style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; max-width: 99.9000015258789%; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: start; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; word-spacing: 0px;">
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;"><br /></span></div>
<div style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; max-width: 99.9000015258789%; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: start; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; word-spacing: 0px;">
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">After President Obama revealed an <span style="background: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; text-decoration: underline; vertical-align: baseline;"><a dataquery="#blog_7E301A3C" href="" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-color: blue; border-bottom-style: dotted; border-left-width: 0px; border-right-width: 0px; border-top-width: 0px; cursor: inherit; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: none; vertical-align: baseline;">ambitious plan</a></span> to support personalized medicine in his 2015 State of the Union address, all eyes turned towards the hope this promise might deliver to families dealing with childhood cancer.</span></div>
<div style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; max-width: 99.9000015258789%; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: start; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; word-spacing: 0px;">
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;"><br /></span></div>
<div style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; max-width: 99.9000015258789%; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: start; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; word-spacing: 0px;">
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">Our General Counsel and resident superdad, Jonathan Agin, profiled how cc-TDI will be part of this promise in his heartfelt, informative column. Read the full piece <span style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: underline; vertical-align: baseline;"><a dataquery="#blog_BD3D2B33" href="" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-color: blue; border-bottom-style: dotted; border-left-width: 0px; border-right-width: 0px; border-top-width: 0px; cursor: inherit; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: none; vertical-align: baseline;">at <span style="background: transparent; border: 0px; font-style: italic; margin: 0px; outline: 0px; padding: 0px; vertical-align: baseline;">HuffPost Impact</span></a></span>.</span></div>
Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-37928068030307042752015-01-20T20:30:00.000-08:002015-02-02T20:32:21.115-08:00Welcoming Matthew (to cc-TDI)<br />
<div style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; max-width: 99.9000015258789%; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: justify; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; word-spacing: 0px;">
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">Matthew Svalina joins cc-TDI from Dr. Keller's academic laboratory as a founding member of our scientific team, with an eye on advancing the most promising childhood cancer therapeutics towards clinical trials. Matthew is motivated by the 1 in 5 children diagnosed with cancer for whom survival is still a challenge.</span></div>
<div style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; max-width: 99.9000015258789%; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: justify; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; word-spacing: 0px;">
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;"><br /></span></div>
<div style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; max-width: 99.9000015258789%; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: justify; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; word-spacing: 0px;">
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">Matthew earned a Bachelor of Science degree in Biological Sciences with a minor in Chemistry from the University of Illinois in 2007. Following completion of his undergraduate degree, Matthew earned a paramedic license through Malcolm X College in Chicago, where he completed his field internship with the Chicago Fire Department on ambulances serving the south side of Chicago. As a member of the Keller lab, Matthew has already co-authored <span style="background: transparent; border: 0px; margin: 0px; outline: 0px; padding: 0px; text-decoration: underline; vertical-align: baseline;"><a dataquery="#blog_31EA7921" href="https://www.blogger.com/blogger.g?blogID=3005276224861707274" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-color: blue; border-bottom-style: dotted; border-left-width: 0px; border-right-width: 0px; border-top-width: 0px; cursor: inherit; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: none; vertical-align: baseline;">two scientific papers</a></span> on childhood cancer, with additional studies nearing submission. Under Dr. Keller's mentorship, Matthew leads basic science and preclinical projects in rhabdomyosarcoma and medulloblastoma. Matthew’s career goal is to be a physician-scientist with training and independent research in neuroscience and neuro-oncology.</span></div>
<div style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; max-width: 99.9000015258789%; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: start; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; word-spacing: 0px;">
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;"><br /></span></div>
<img data-cke-saved-src="http://static.wixstatic.com/media/64891b_5f9535f3e38043199a04bf01db6dc3fc.jpg" src="http://static.wixstatic.com/media/64891b_5f9535f3e38043199a04bf01db6dc3fc.jpg" height="320" style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; clear: both; cursor: default; display: block; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 19.6000003814697px; margin-bottom: 10px; margin-left: auto; margin-right: auto; margin-top: 10px; max-width: 100%; outline-color: rgb(0, 153, 255); outline-style: solid; outline-width: 2px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: start; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; width: 140.520843505859px; word-spacing: 0px;" width="320" wix-comp="{"id":"innercomp_txtMedia1462","dataQuery":"txtMedia1462","propertyQuery":"txtMedia1462","componentType":"wysiwyg.viewer.components.WPhoto","styleId":"","skin":"wysiwyg.viewer.skins.photo.NoSkinPhoto","display":"block","marginLeft":"auto","marginRight":"auto","dimsRatio":1.3333333333333333,"defaultWidth":576,"width":0.24,"src":"http://static.wixstatic.com/media/64891b_5f9535f3e38043199a04bf01db6dc3fc.jpg","alt":"Matthew Svalina"}" /><br />
<div style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; max-width: 99.9000015258789%; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: start; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; word-spacing: 0px;">
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;"> </span></div>
Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-11843791707248977022015-01-18T20:28:00.000-08:002015-02-02T20:30:01.587-08:00Postdoctoral Fellowship Available<br />
<div style="-webkit-text-stroke-width: 0px; background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; max-width: 99.9000015258789%; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-align: justify; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; word-spacing: 0px;">
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">We are now taking applications for a postdoctoral fellowship studying the tumor microenvironment in the childhood cancer of muscle, rhabdomyosarcoma. This mentored position will explore at depth the cell-cell communication and signaling pathways responsible for tumor initation and progression. A strong publication record and sense of exploration are requisite. Candidates with PhD degrees in the biological sciences <span style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; font-style: italic; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; vertical-align: baseline;">as well as engineering</span> are invited to apply. For more information, contact Charles Keller, MD at <span style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; border-bottom-width: 0px; border-color: initial; border-left-width: 0px; border-right-width: 0px; border-style: initial; border-top-width: 0px; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: underline; vertical-align: baseline;"><a dataquery="#blog_9ABB8716" href="" style="background-attachment: initial; background-clip: initial; background-color: transparent; background-image: initial; background-origin: initial; background-position: initial initial; background-repeat: initial initial; border-bottom-color: blue; border-bottom-style: dotted; border-left-width: 0px; border-right-width: 0px; border-top-width: 0px; cursor: inherit; margin-bottom: 0px; margin-left: 0px; margin-right: 0px; margin-top: 0px; outline-color: initial; outline-style: initial; outline-width: 0px; padding-bottom: 0px; padding-left: 0px; padding-right: 0px; padding-top: 0px; text-decoration: none; vertical-align: baseline;">charles@cc-tdi.org</a></span>. </span></div>
<img data-cke-saved-src="http://static.wixstatic.com/media/64891b_5d4e323ebf0a4992ad3ce286d7d3d729.jpg" src="http://static.wixstatic.com/media/64891b_5d4e323ebf0a4992ad3ce286d7d3d729.jpg" style="-webkit-text-stroke-width: 0px; background: transparent; border: 0px; clear: both; color: #555555; cursor: default; display: block; font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: 19.6000003814697px; margin: 10px auto; max-width: 100%; orphans: auto; outline: rgb(0, 153, 255) solid 2px; padding: 0px; text-align: start; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; widows: auto; width: 286.909729003906px; word-spacing: 0px;" wix-comp="{"id":"innercomp_txtMediag4f","dataQuery":"txtMediag4f","propertyQuery":"txtMediag4f","componentType":"wysiwyg.viewer.components.WPhoto","styleId":"","skin":"wysiwyg.viewer.skins.photo.NoSkinPhoto","display":"block","marginLeft":"auto","marginRight":"auto","dimsRatio":0.6217494089834515,"defaultWidth":423,"width":0.49,"src":"http://static.wixstatic.com/media/64891b_5d4e323ebf0a4992ad3ce286d7d3d729.jpg"}" /><div style="-webkit-text-stroke-width: 0px; background: transparent; border: 0px; color: #555555; font-family: arial, 'ms pゴシック', 'ms pgothic', 돋움, dotum, helvetica, sans-serif; font-size: 14px; font-stretch: normal; font-style: normal; font-variant: normal; font-weight: normal; letter-spacing: normal; line-height: normal; margin: 0px; max-width: 99.9000015258789%; orphans: auto; outline: 0px; padding: 0px; text-align: start; text-indent: 0px; text-transform: none; vertical-align: baseline; white-space: normal; widows: auto; word-spacing: 0px;">
</div>
<div>
<br /></div>
Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-42762395718498565402014-12-25T13:51:00.003-08:002014-12-26T07:56:26.821-08:00Nobel medal sold... then given back<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgAu6Y30UtjF7LM6xeznBWQs2Dbok38M-HI9nGu1JFZsv18-obWZC6oSd32CZLRcm8qyoymgCZAPjuwONMFyY_pNgm7NNqCQFA-ODyj2mWzk7Qd6eyXv-imUKeW2bQj8a3-emXGyZug1aU/s1600/watson-nobel-medal.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEgAu6Y30UtjF7LM6xeznBWQs2Dbok38M-HI9nGu1JFZsv18-obWZC6oSd32CZLRcm8qyoymgCZAPjuwONMFyY_pNgm7NNqCQFA-ODyj2mWzk7Qd6eyXv-imUKeW2bQj8a3-emXGyZug1aU/s1600/watson-nobel-medal.jpg" height="200" width="133" /></span></a><span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">To read the improbably story of an altruistic gift to science, followed by another gracious gift, see the story by Daniel Dunaief <a href="http://www.northshoreoflongisland.com/Articles-News-i-2014-12-11-100784.113114-sub-DNA-scientist-at-center-of-Nobel-prize-boomerang.html">here</a>. </span><br />
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;"> </span><br />
<span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif; font-size: x-small;">[ image source is the original news story website ]<span id="goog_732200122"></span><span id="goog_732200123"></span><a href="https://www.blogger.com/"></a></span>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-90383242197207933332014-12-08T10:21:00.002-08:002014-12-08T10:21:40.892-08:00Be a Dog's Best Friend <a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjJrYTQSlvuCeEvMBf23MQ8xXKRNv7gLDex_efARJuyDenumMK6Iuoi3slws0P4FKa8et36cscNtJfPEzOcxFtarQjHoqbLAkhON262bcUpVnFinkh5aYJ1qd_7SEyZ3F04pYkyhSKWqQI/s1600/DSC_0635.tif" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjJrYTQSlvuCeEvMBf23MQ8xXKRNv7gLDex_efARJuyDenumMK6Iuoi3slws0P4FKa8et36cscNtJfPEzOcxFtarQjHoqbLAkhON262bcUpVnFinkh5aYJ1qd_7SEyZ3F04pYkyhSKWqQI/s1600/DSC_0635.tif" height="159" width="200" /></a><span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">Can finding new treatments for dogs with soft tissue sarcomas also help develop new drugs for children and adults with soft tissue sarcomas? This possibility is raised by today's publication by collaborator Milan Milovance entitled, <span style="text-decoration: underline;"><a href="http://www.ncbi.nlm.nih.gov/pubmed/25435513" target="_blank"><span style="font-style: italic;">Comparative Pathology of Canine Soft Tissue Sarcomas: Possible Models of Human Non-rhabdomyosarcoma Soft Tissue Sarcoma</span></a></span>. Co-authors of this study include Charles, as well as long time collaborator adult sarcoma pathologist, Atiya Mansoor. [ pictured: undifferentiated sarcoma (also called UPS, or MFH) in dog and human ] </span>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-68817944770632604902014-12-06T12:09:00.000-08:002014-12-06T12:09:58.325-08:00The Art of Survivorship<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjIDPsTkYt9zDIMQ9Ql3j4gSzOPlCgJ9k_9QWw6be-1xrqd2Wfhrv3TvoXHWQChMRggIG2nEt7koGMm7ZSYnVZNXB_bLueM8WiDRzQLWrv0fALpOylgLLJPgYtlOdNH2VJW9j5An1VMjOc/s1600/April-Charles-at-Tinys_rev.jpg" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><span style="font-family: Arial, Helvetica, sans-serif;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjIDPsTkYt9zDIMQ9Ql3j4gSzOPlCgJ9k_9QWw6be-1xrqd2Wfhrv3TvoXHWQChMRggIG2nEt7koGMm7ZSYnVZNXB_bLueM8WiDRzQLWrv0fALpOylgLLJPgYtlOdNH2VJW9j5An1VMjOc/s1600/April-Charles-at-Tinys_rev.jpg" height="148" width="200" /></span></a><br />
<div class="MsoNormal">
<span style="font-family: Arial, Helvetica, sans-serif;">This month the collection, "<i>Mother & Son: The Art of a Mom’s Journey through Childhood Cancer
with Her Son</i>" will be on display at Tiny’s Coffee 1412 SE 12th
Portland, Oregon. The artist, April, is
an advocate for childhood cancer survivorship, her son now thriving after a
challenging period with sarcoma. The
mixed media of paint-on-radiograph is accompanied by the history, from a
mother's perspective, of the experience. </span><o:p></o:p></div>
<div class="MsoNormal">
<o:p></o:p></div>
Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-38283499677706634572014-10-31T19:57:00.000-07:002014-10-31T20:01:34.128-07:00AACR Pediatric Cancer Think-Tank<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjzdvrrep6nfIRq1lei1DGmXareLP_Yk73PMQwkalTPzur3oR37MOi5LZJPM9tEq-SJOAeElkFSll8r3GCDe6XvIdljk1nGVFkHhKzGpZyv0j8gALYop_P3e9-N1x35-2a9Ykp0LpUa894/s1600/philly.JPG" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><span style="font-family: Arial, Helvetica, sans-serif;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEjzdvrrep6nfIRq1lei1DGmXareLP_Yk73PMQwkalTPzur3oR37MOi5LZJPM9tEq-SJOAeElkFSll8r3GCDe6XvIdljk1nGVFkHhKzGpZyv0j8gALYop_P3e9-N1x35-2a9Ykp0LpUa894/s1600/philly.JPG" height="150" width="200" /></span></a><span style="font-family: Arial, Helvetica, sans-serif;">This week the AACR held a think-tank in Philadelphia on the critical issues in childhood cancer research and care delivery. In attendance were 43 invitees from universities, pharmaceutical companies and patient advocacy groups. Topics included prevention (yes, prevention!), improved care for hereditable cancer predispositions, making drugs available for children with cancer, and the promise of genomics in delivering personalized cancer care. Charles presented on the topic that not only mutation but also cell of origin strongy influences response to treatment - and the types of epigenetic therapies that can be given. </span>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-48189466046088544532014-10-20T18:37:00.000-07:002014-10-20T18:37:08.928-07:00exciting news<div style="text-align: left;">
<span style="clear: right; float: right; font-family: Arial, Helvetica, sans-serif; margin-bottom: 1em; margin-left: 1em;"></span><div style="text-align: left;">
<span style="clear: right; float: right; font-family: Arial, Helvetica, sans-serif; margin-bottom: 1em; margin-left: 1em;"><a href="http://static.wixstatic.com/media/64891b_2b451cbce8c64689bdfc22cf2394f3ee.jpg_srz_p_159_170_75_22_0.50_1.20_0.00_jpg_srz" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" height="200" src="http://static.wixstatic.com/media/64891b_2b451cbce8c64689bdfc22cf2394f3ee.jpg_srz_p_159_170_75_22_0.50_1.20_0.00_jpg_srz" width="186" /></a>How much is a tumor like a wound? Will tumor cells interact with the body's normal muscle stem cells, co-opting them for advantage to the tumor? Can IL-4 Receptor antibodies block this process? These are the questions in our NIH R01 grant application that was scored this week in the top 4% of grants for that review cycle (usually, the top 9% of grants are funded). We're very excited about this grant, and the probable 5 years of funding to pursue these question that we think will benefit patients with rhabdomyosarcoma in a tangible way. Kudos to Megan, who took strong work by Imran, Tohru and GH to the next level and made this project possible. </span></div>
<br />
</div>
Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0tag:blogger.com,1999:blog-3005276224861707274.post-5025355891447558442014-10-07T19:21:00.000-07:002014-10-07T19:21:08.916-07:00SARC SPORE meeting<a href="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiHOX4Dos8DcPwRgLsUCe2bNEA_yYkjd4djWmWqk6CDVXojyp7snXAPSl1-P-M4QJLi-_Enx2E551mQ_7geQCLGe85VFHtNkTdO9icYkXUkil4KAJjPopOjbv6WSdWryOBxxMUor3FkgMQ/s1600/DC.JPG" imageanchor="1" style="clear: right; float: right; margin-bottom: 1em; margin-left: 1em;"><img border="0" src="https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEiHOX4Dos8DcPwRgLsUCe2bNEA_yYkjd4djWmWqk6CDVXojyp7snXAPSl1-P-M4QJLi-_Enx2E551mQ_7geQCLGe85VFHtNkTdO9icYkXUkil4KAJjPopOjbv6WSdWryOBxxMUor3FkgMQ/s1600/DC.JPG" height="161" width="200" /></a><span class="Apple-style-span" style="font-family: Arial, Helvetica, sans-serif;">We presented our research project in collaboration with <a href="http://www.langenaulab.com/">Dr. David Langenau</a> (MGH) at today's <a href="http://www.sarctrials.org/">SARC</a> clinical trial consortium SPORE meeting - we are grateful for this 2 year pilot project funding. Differentiation as a therapy for rhabdomyosarcoma? possibly! </span>Charleshttp://www.blogger.com/profile/07158999231951419025noreply@blogger.com0